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Abstract
Background The clinical characteristics of human meta-
pneumovirus (hMPV)-associated lower respiratory tract
infection (LRTI) after allogeneic hematopoietic stem cell
transplantation (HSCT) is not well described. We describe
the clinical course in eight HSCT recipients suffering from
hMPV infection.
Methods We prospectively included all patients with
hMPV-associated LRTI after allogeneic HSCT during a
period of 1 year. hMPV was diagnosed by multiplex
polymerase chain reaction (PCR) from bronchoalveolar
lavage (BAL).
Results Eight patients with hMPV-associated LRTI were
identified from 93 BAL samples. Three of the eight
patients had co-infections with other pathogens. The
median age of the patients was 45 years [interquartile
range (IQR) 36.8–53.5], the median time posttransplant
was 473 days (IQR 251–1,165), 5/8 patients had chronic
graft-versus-host disease (cGvHD), and 6/8 patients
received immunosuppression. Chest computed tomography
(CT) scanning showed a ground-glass pattern in 7/8
patients. Seven of eight patients required hospitalization
due to severe symptoms and hypoxemia. All were treated
with intravenous immunoglobulin (IVIG), which was
combined with oral ribavirin in six patients. The mortality
rate was 12.5 % (1/8).
Conclusions hMPV-associated LRTI in allogeneic HSCT
recipients are not uncommon and present with unspecific
respiratory symptoms, ground-glass pattern in CT scan-
ning, and co-infection.
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Introduction
Respiratory tract infections (RTIs) are common reasons for
the consultation of allogeneic hematopoietic stem cell
transplantation (HSCT) recipients in outpatient clinics [1].
In recent years, ‘‘new’’ respiratory viruses, such as human
metapneumovirus (hMPV) and coronaviruses, were dis-
covered and associated with severe morbidity and mortality
in the immunocompromised host [1–3].
hMPV is a single-strand negative RNA virus and belongs
to the family of paramyxoviridae, together with respiratory
syncytial virus (RSV) and parainfluenza viruses. hMPV can
be isolated from respiratory samples from otherwise healthy
children with upper/lower (U/L)-RTIs [4]. Seroepidemio-
logical studies indicate a 90 % exposure until adulthood. In
HSCT recipients, hMPV-associated LRTIs have been
associated with considerable morbidity and mortality [5, 6].
Only a few clinical studies have addressed the clinical
presentation, risk factors, and the clinical course.
Methods
Patients
Between June 2009 and June 2010, all patients following
allogeneic HSCT with symptoms of LRTI were further
examined by computed tomography (CT) scanning and, in
case of pulmonary infiltrates, underwent a bronchoalveolar
lavage (BAL) with microbiological work-up. LRTI was
defined by the presence of coughing, dyspnea, and/or
pulmonary infiltrates in CT chest scans [7].
Following an index case of hMPV infection, polymerase
chain reaction (PCR) for hMPV was routinely included in
the diagnostic work-up.
After diagnosis, clinical and laboratory parameters
(including blood count, C-reactive protein, and immuno-
globulins) were analyzed and reevaluated prospectively up
to 4 weeks. Furthermore, additional clinical and laboratory
data were collected from the charts retrospectively. All
patients gave written informed consent [approved by the
local Institutional Review Board (IRB) EKBB-363/09].
The degree of immunodeficiency was classified
according to clinical and laboratory criteria as described
previously [8]. Patients with allogeneic HSCT [6 months
prior to hMPV diagnosis, acute graft-versus-host disease
(aGvHD) grade \2, leukocyte count [2.0 9 109/L, lym-
phocyte count [0.1 9 109/L, recipients of maintenance
immunosuppressive drugs, or T cell or B cell depletion
[3 months prior to hMPV diagnosis were classified as
moderately immunodeficient. In case of HSCT \6 months
prior to hMPV diagnosis, T cell or B cell depletion
\3 months prior to diagnosis, aGvHD-grade [2,
leukopenia \2.0 9 109/L, lymphopenia \0.1 9 109/L, or
hypogammaglobulinemia \4.0 g/L, immunodeficiency
was classified severe.
Diagnostics of viral infection
In all patients, BAL samples were analyzed with an estab-
lished multiplex PCR assay (RespiFinder) [9]. Respi-
Finder is able to detect 14 RNA viruses, one DNA
virus, and four bacteria: adenovirus, Bordetella pertussis,
Chlamydophila pneumoniae, coronavirus 229E/NL63/
OC43, hMPV, influenza A/B, influenza A/H5N1, Legionella
pneumophila, Mycoplasma pneumoniae, parainfluenza
types 1 to 4, respiratory syncytial virus A/B, and rhinovirus
[10]. For infection control reasons, all patients were screened
weekly by nasopharyngeal swabs during outpatient follow-
up until they became negative with the same assay.
Cytopathological work-up
Standardized cytopathological work-up of BAL samples
included absolute cell counts, immunophenotyping of lym-
phocytes, and immunostaining for RSV, cytomegalovirus
(CMV), and influenza virus. Standardized bacteriological
cultures to identify bacteria, fungi, and mycobacteria were
performed.
Radiological work-up
CT images were analyzed by two independent radiologists
being aware of clinical findings, underlying disease, and
posttransplant immunodeficient status. Images were com-
pared retrospectively with earlier and later series within a
4-week period of time.
Data analysis
The SPSS 13 software package (http://www.SPSS.com)
was used to calculate the medians and interquartile ranges
(IQRs). We used non-parametric tests due to the non-nor-
mal data distributions.
Results
Patient characteristics
Between June 2009 and June 2010, eight cases of hMPV-
associated LRTI were identified among 93 patients
undergoing bronchoscopy and BAL for LRTI. The overall
incidence of hMPV-associated LRTI was, hence, 8.6 %.
The median time posttransplant was 473 days (IQR
251–1,165). Five patients had chronic graft-versus-host
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disease (cGvHD) and four of these patients had previously
biopsy-proven bronchiolitis obliterans and were immuno-
suppressed with prednisone, tacrolimus, and mycophenolic
acid (Table 1). Six cases occurred during March and April
2010. The infections were not epidemiologically related
and we could not identify contact exposures between
patients. The clinical characteristics at diagnosis are pre-
sented in Table 1. The performance score (Karnofsky
scale) was decreased by 20 % compared to previous visits
(median before = 90 %, median at diagnosis = 70 %). Dry
cough and fever were commonly present (in 8/8 and 7/8
patients, respectively) at diagnosis, whereas only half of
the patients presented with a runny nose or dyspnea New
York Heart Association (NYHA) score [II.
Laboratory findings
At diagnosis, the median total lymphocyte count was sig-
nificantly lower compared to 4 weeks earlier (778 vs.
1,378/lL, p = 0.04) and the C-reactive protein (CRP) level
was significantly higher (41.3 vs. 3.7 mg/L, p = 0.005).
Hemoglobin, neutrophil, platelet, and immunoglobulin
levels remained unchanged. Four weeks after diagnosis,
only IgG levels (8.8 vs. 16.9 g/L, p = 0.032) and reticu-
locyte count increased (67 vs. 120/lL p = 0.0457) after
therapeutic interventions (see below), whereas the hemo-
globin, neutrophil, lymphocyte, platelet, IgA, and IgM
levels did not change significantly.
Radiologic findings
Prior to BAL, a chest CT scan was performed in each
patient. The typical CT findings of two patients are shown
in Fig. 1. Although CT findings are unspecific for viral
infections, ground-glass pattern opacities were the most
frequent findings, detected in 7/8 patients, but nodules with
halo (5/8) and alveolar/interstitial infiltrates (4/8) were also
common findings. In 6/8 patients, expiratory imaging was
performed. In these patients, no air trapping as a sign for
active bronchiolitis obliterans was present.
Spirometry findings
At the time of diagnosis, spirometry findings indicated a
drop in the FEV1 of 20 % of the median as compared to
earlier spirometry. CO diffusion capacity was slightly
reduced. Parameters were restored to baseline levels
2 months after infection.
Results of bronchial lavage and co-infections
At the initial diagnosis of hMPV infection, co-infections
were observed in three patients: one with rhinovirus in the
nasopharyngeal swab, one with Moraxella catarrhalis in
BAL, and one with coronavirus OC43 in BAL, respec-
tively. Notably, during outpatient follow-up, nasopharyn-
geal swab screening could only repeatedly detect hMPV in
patients with initial co-infection indicated in previous BAL
samplings. No fungal or mycobacterial co-infections were
detected. No CMV reactivation was present. The findings
of BAL fluids are summarized in Table 2. At the time of
diagnosis of hMPV infection, cytology in BAL showed
predominant macrophages (67 %) and lymphocytes
(10 %). It is important to note that patient 1 was in marrow
aplasia at the time of BAL, which explains why only a few
lymphocytes (6 9 106/L) were observed (Table 2). For
patient 6, BAL was performed for virological diagnosis
but, unfortunately, no quantitative differential cell count
was done.
Treatment and outcome of hMPV-associated LRTI
Treatment
All patients were treated with weekly intravenous immu-
noglobulin (IVIG) 0.5 g/kg bodyweight. The median
treatment duration was 3 weeks. Furthermore—based on
expert opinion and Bonney et al. [11]—six patients
received oral ribavirin, starting with a loading dose of
600 mg on the first day, 200 mg TID for the next 2 days,
with a further increase of the dosage every 2 days until a
maximum dose of 600 mg TID was reached. The median
duration of ribavirin treatment was 17 days, with four
patients receiving the maximum dose for a median time of
1 week. Treatment with ribavirin was based on the decision
by the treating physician, depending on the clinical
manifestations.
Treatment-related complications
Overall, treatment was well tolerated, with no significant
adverse events, except for the requirement of red blood cell
(RBC) transfusion support, which was needed in 4/6 riba-
virin-treated patients, due to the well-known adverse effect
of ribavirin on RBCs and erythropoiesis [12]. Hemoglobin
levels started to decrease in ribavirin-treated patients after
7 days of treatment. Due to low hemoglobin levels and
associated symptoms of anemia, 4/6 patients treated with
ribavirin required a total of 24 erythrocyte transfusions.
Outcome
Seven of eight patients (87.5 %) required hospitalization
due to poor clinical condition, indicated by a reduced
Karnofsky scale score and a dyspnea NYHA score of III.
Metapneumovirus infection after stem cell transplantation 679
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No further specified score was used to decide on the
requirements of hospitalization.
One patient (number 1) required intensive care and
assisted ventilation. Despite immediate treatment with
IVIG and oral ribavirin, rapid respiratory failure and
exhaustion developed and the patient died 39 days after the
diagnosis of hMPV pneumonia from multi-organ failure.
This patient has been infected within 30 days of trans-
plantation. Surviving patients became asymptomatic (i.e.,
no coughing or sneezing, dyspnea NYHA score\II) after a
median of 21 days. Seven of eight patients were discharged
with clinically improved conditions after a median of
13 days. Treatment was stopped when clinical and labo-
ratory improvement was observed or hMPV was no longer
detectable in nasopharyngeal swab screening. hMPV in
nasopharyngeal swabs could no longer be detected after a
median of 2 weeks. Overall, clinical recovery was excel-
lent 2 months after infection, indicated by a 90 % Kar-
nofsky score. Respiratory recovery as assessed by the lung
function test was reached in the same time period.
Discussion
During a period of 1 year, we could identify eight cases of
hMPV-associated LRTI in patients following allogeneic
HSCT, as found in the BAL of patients undergoing bron-
choscopy because of respiratory symptoms and infiltrates
in CT scan. The literature on hMPV infections following
allogeneic or autologous HSCT is still scarce [13–19] and
often incomplete. Conditioning regimens, remission status,
immunosuppression, and laboratory data, clinical signs and
symptoms, and duration of illness, as well as diagnostic
microbiological methods, are often not reported.
Our prospective data show that hMPV is not uncommon.
Even later than 1 year after transplantation, hospitalization
was required in the majority of patients due to a reduction
in performance scores and drop in lung function. Initial
clinical signs of hMPV infection are unspecific [1, 20] and
similar to other viral infections. Chest CT scans predomi-
nantly showed a ground-glass pattern, which is also an
unspecific and common finding in patients with other viral
infections [18]. We, therefore, recommend bronchoscopy
for patients suffering from LRTI and showing a ground-
glass pattern in the CT scan. This does not only allow for
the searching of viral infection using a multiplex PCR, but
also for concomitant bacterial infection.
Short interval from transplant to infection, intensive
immunosuppression, as well as preexisting pulmonary
Fig. 1 Chest computed tomography (CT) findings at diagnosis.
Patients are marked according to the code used in the tables. The
arrows indicate ground-glass pattern
Table 2 Bronchoalveolar
lavage findings
Patient 2 was diagnosed only by
nasopharyngeal swab. No BAL
was performed. For patient 6,
BAL was available, but no
quantitative differential count of
leukocytes was performed
F female, M male, HPF high
power field at standard
microscopy
Patient Age
(years)/
gender
Macrophages %
(cells 9 106/L)
Lymphocytes %
(cells 9 106/L)
Neutrophils %
(cells 9 106/L)
Eosinophils %
(cells 9 106/L)
Mast
cells/
HPF
1 51/F 84 (97.4) 5 (6) 10 (12) 1.1 (1) 0
2 37/F – – – – –
3 36/F 84 (99.54) 12 (14) 2 (2) 2 (2) 0
4 27/M 80 (203) 15 (38) 5 (13) 0 (0) 0
5 57/F 38 7 55 0 0
6 38/F – – – – –
7 54/M 54 (188) 8 (28) 38 (132) 0 (0) 0
8 53/M 38 (83.6) 32 (70) 30 (66) 0 (10) 10
Median 67 % 10 % 20 % 0 % 0/HPF
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123
alterations like bronchiolitis obliterans may affect the
clinical course of hMPV, as well as other viral infections
[8, 21]. Hence, the importance of single or combinations of
risk factors needs to be examined in larger studies.
The outcome of our patients was favorable, except for
one patient who suffered from hMPV infection shortly after
transplantation (overall survival 87.5 %). A significantly
lower mortality rate was observed in our patients compared
to the literature, where mortality rates of up to 50 % are
reported. However, most of these patients with a poor
outcome suffered from hMPV infection which occurred
within the first month posttransplant (Table 3). The lack
of reports of infections in the later posttransplant
period clearly indicates a potential underreporting or
Table 3 Review of the literature
Patient
no.
Age Gender Basic
disease
Type of
graft
Time
postTx
Co-infection Treatment Outcome Reference
1 63 Male MM Auto 1,885 None None Died Huck et al.
[19]
2 46 Male MM Allo 8 None Corticosteroids Died, idiopathic
pneumonia
Englund
et al.
[17]3 54 Female MDS Allo 22 None Aerosolized
ribavirin
Died, idiopathic
pneumonia and sepsis
4 24 Female ALL Auto 18 HSV None Survived, but died on
relapse of disease
5 30 Male AML Allo 0 Parainfluenza
virus
Corticosteroids Died, aGvHD,
parainfluenza
pneumonia, shock
6 46 Male AML Allo 13 None Corticosteroids Died, idiopathic
pneumonia
7 33 Female ALL Allo 7 – None Died Cane et al.
[16]
8 na Female CML Allo 19 Pneumonia,
RSV
na Survived Oliveira
et al.
[15]9 na Male NHL Auto 2 Pneumonia na Survived
10 na Male ALL Allo 10 Sepsis,
influenza B
na Died
11 na Female MM Auto 277 RSV na Survived
12 na Male PNH Allo 0 None na Survived
13 na Male CML Allo 17 Pneumonia na Survived
14 na Male CML Allo 0 None na Survived
15 na Female CML Allo 0 None na Survived
16 na Female CML Allo 46 None na Survived
17 na Male CML Allo 28 None na Survived
18 na Female SAA Allo 97 None na Survived
19 40 Female Hodgkin Allo 101 Influenza A,
coronavirus
Oseltamivir Died on day 112 Campbell
et al.
[13]
20 58 Female na na na None na unknown Franquet
et al.
[18]
21 27 Male na na na None na unknown
22 58 Male na na na None na unknown
23 23 Male na na na None na unknown
24 44 Male na na na None na unknown
Median 44
(30–54)
14 male
10
female
15 allo
4 auto
5 not
available
17
(4.5–37)
8 died, 11 survived, 5
unknown
na information not available, MM multiple myeloma, MDS myelodysplastic syndrome, ALL acute lymphatic leukemia, AML acute myeloic
leukemia, CML chronic myeloic leukemia, NHL non-Hodgkin lymphoma, PNH paroxysmal night hemoglobinuria, SAA severe anaplastic
anemia, HSV herpes simplex virus, RSV respiratory syncytial virus
682 A. Egli et al.
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underdiagnosis, as only a few centers perform BAL in
patients with lower respiratory symptoms. The remarkable
better survival in our patients might be due to early diag-
nosis and the improved ‘‘net state of immunity’’. Most of
our patients had persistent immunosuppressive treatment
because of cGvHD or—like in patient 6—immunosup-
pressive treatment has been stopped only a few weeks
before infection and had to be restarted later due to the
clinical relapse of cGvHD. We, therefore, speculate that
cGvHD and immunosuppressive treatment is a risk factor
for clinically relevant hMPV infection.
We cannot clarify if the treatment with IVIG and riba-
virin was responsible for the therapeutic effect and the
good outcome due to the lack of a control group. However,
case reports and small case series have described favorable
outcomes upon treatment with ribavirin and IVIG [11, 22].
IVIG treatment was given in all our cases, but the amount
of hMPV-neutralizing antibodies in IVIG formulations
remains unclear. Randomized studies on the hMPV treat-
ment are still missing and will be difficult to perform due to
the relatively small case number in single centers. Rec-
ommended treatment with ribavirin is based on expert
opinion [3, 23], which is supported by data from in vitro
cell cultures and mouse models [24]. In our center, we use
oral ribavirin in severely immunocompromised patients
with hMPV infection. This was well tolerated, except for
hemolysis with the need for repetitive RBC transfusions.
This needs to be considered as a severe side effect. Hence,
a careful analysis of the potential risks and benefits is
recommended before making the decision to start ribavirin
treatment in selected patients with severe infection. Several
other treatment strategies were described in the literature.
Patients treated with corticosteroids, aerosolized ribavirin,
or oseltamivir did not survive [13, 15–19].
Limitations of our study are the relatively small number
of patients with hMPV LRTI, the single-center approach,
and the lack of a proper control group for our treatment
approach. However, due to the availability of clinical and
laboratory data, including lung function tests and CT scans,
we are able to properly describe the clinical course of
hMPV LRTI in recipients of allogeneic HSCT.
In summary, hMPV infection is not uncommon in
allogeneic HSCT recipients, even later than 1 year after
transplantation. In our case series, most patients suffered
from persistent immunosuppression and/or cGvHD. If
patients suffer from respiratory symptoms and a ground-
glass pattern in the CT scan, we recommend BAL with
specific viral testing. If patients are treated with IVIG and
ribavirin, the clinical outcome of hMPV infection is good.
Due to ribavirin-associated hemolysis, the drug needs to be
given with caution. The effectiveness and safety of a
combined treatment with IVIG and ribavirin needs to be
assessed in prospective therapeutic trials.
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